Natalizumab Completed Phase 4 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Supportive Care

IndicationsStatusPurposePhase
CompletedSupportive Care4
clinicaltrials.gov IdentifierTitleDrugs
NCT01591551NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness